KumpfelTGiglhuberKAktasO, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – Revised recommendations of the Neuromyelitis Optica Study Group (NEMOS) – Part II: Attack therapy and long-term management. J Neurol2024; 271: 141–176.
2.
SiriratnamPHudaSButzkuevenH, et al. Risks and outcomes of pregnancy in neuromyelitis optica spectrum disorder: A comprehensive review. Autoimmun Rev2024; 23(2): 103499.
3.
Mao-DraayerYThielSMillsEA, et al. Neuromyelitis optica spectrum disorders and pregnancy: Therapeutic considerations. Nat Rev Neurol2020; 16(3): 154–170.
4.
VukusicSMarignierRCironJ, et al. Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society. Mult Scler2023; 29(1): 37–51.
5.
GuerraTPaolicelliDIaffaldanoP. Eculizumab treatment during pregnancy in a patient with AQP4-IgG-seropositive NMOSD: A case report. Mult Scler J2025.
6.
SociéGCaby-TosiMPMarantzJL, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol2019; 185(2): 297–310.
